M
MADRIGAL PHARMACEUTICALS INC
NASDAQ: MDGL (Madrigal Pharmaceuticals, Inc.)
最近更新时间: 1小时之前515.34
5.30 (1.04%)
| 前收盘价格 | 510.04 |
| 收盘价格 | 502.92 |
| 成交量 | 271,477 |
| 平均成交量 (3个月) | 362,317 |
| 市值 | 11,906,481,152 |
| 价格/销量 (P/S) | 9.09 |
| 股市价格/股市净资产 (P/B) | 22.48 |
| 52周波幅 |
| 营业毛利率 | -123.38% |
| 营业利益率 (TTM) | -57.79% |
| 稀释每股收益 (EPS TTM) | -17.83 |
| 总债务/股东权益 (D/E MRQ) | 16.85% |
| 流动比率 (MRQ) | 5.91 |
| 营业现金流 (OCF TTM) | -395.31 M |
| 杠杆自由现金流 (LFCF TTM) | -274.11 M |
| 资产报酬率 (ROA TTM) | -25.56% |
| 股东权益报酬率 (ROE TTM) | -50.16% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Madrigal Pharmaceuticals, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.50 |
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 7.73% |
| 机构持股比例 | 108.28% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Baker Bros. Advisors Lp | 31 Mar 2026 | 2,141,701 |
| Avoro Capital Advisors Llc | 31 Mar 2026 | 1,818,181 |
| Paulson & Co. Inc. | 31 Mar 2026 | 1,392,188 |
| Wellington Management Group Llp | 31 Mar 2026 | 694,958 |
| William Blair Investment Management, Llc | 31 Mar 2026 | 340,519 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合